Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and

Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs,

With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood